JERSEY CITY, N.J., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Drug development company SCYNEXIS, Inc. (NASDAQ:SCYX) today announced that the Company will participate in the following upcoming investor conferences:
Canaccord Genuity Rare Disease Conference at the InterContinental New York Barclay Hotel in New York City on Tuesday, February 7, 2017.
RBC Capital Markets Global Healthcare Conference at the Lotte New York Palace Hotel in New York City on Wednesday, February 22, 2017. The Company will present at 3:35 p.m. ET.
A live webcast of the RBC presentation will be available on the Investors section of the Company's website: www.scynexis.com. A replay of the presentation will be available approximately two hours after the event and will be available for two weeks following the presentation.
Top Company Interviews
SCYNEXIS is a pharmaceutical company committed to the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. We are developing our lead product candidate, SCY-078, as an oral and IV drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. For more information, visit www.scynexis.com.
Blair McCarthy Atkinson
MacDougall Biomedical Communications
SCYNEXIS Inc. published this content on 31 January 2017 and is solely responsible for the information contained herein. Distributed by Public, unedited and unaltered, on 31 January 2017 14:10:10 UTC.